COG-D9902
| Clinical Trial Title | Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma |
| Trial Status | Closed to Enrollment |
| Start Date | 10/25/2005 |
| Location | Randall Children's Hospital at Legacy Emanuel |
| Trial Type | Pediatric Cancer (Oncology) |
| Specific Condition | Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Unclassified soft tissue sarcoma, and Other soft tissue neoplasms (excluding benign tumors). |
| Description | A COG soft tissue sarcoma diagnosis, biology and banking protocol. Patients enrolled on D9902 fall into one of three groups: Category 1: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review stratum of D9902. Category 2: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review and Biology/Banking strata of D9902. Category 3: Patients NOT planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can only enroll on the Biology/Banking stratum of D9902. Pathology Central Review will not be performed for clinical purposes or to meet any of the research objectives, except to establish the bank. The enrolling investigator/institution will not receive a report back from COG regarding the submitted sample. |
| Eligibility Criteria | Age: patients must be < 50 years of age at the time of enrollment Patients must have one of the following histologically-confirmed diagnoses: Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), unclassified soft tissue sarcoma that is too undifferentiated to be placed in a specific pathologic category in the WHO classification, and other soft tissue neoplasms, excluding benign tumors Patients with malignant rhabdoid tumor, Ewing sarcoma/PNET, or ostogenic sarcoma of bone are NOT eligible for enrollment on D9902 |
| IRB Number | |
| Notes | https://clinicaltrials.gov/ct2/show/NCT00919269 Study status is: Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred). |
| Principal Investigator | Janice Olson, MD |
| Contact Name | Children's Cancer and Blood Disorders Program |
| Contact Phone | (503) 276-9300 |
| Contact Fax | |
| Contact E-Mail |
